zorevunersen   Click here for help

GtoPdb Ligand ID: 14721

Synonyms: STK-001 | STK001
Compound class: Nucleic acid
Comment: Zorevunersen (STK-001) is an antisense oligonucleotide (ASO) that targets sodium voltage-gated channel alpha subunit 1 (SCN1A) pre-mRNA transcript, to promote an increase in Nav1.1 channel protein in neurons. It is intended as a disease-modifying treatment for Dravet syndrome, where SCN1A haploinsufficiency disrupts Nav1.1 protein production.

Full sequence is:
all-P-ambo-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine
No information available.
Summary of Clinical Use Click here for help
Zorevunersen (STK-001) was progressed as a clinical candidate to evaluate its potential as a disease-modifying treatment for SCN1A-related Dravet syndrome [1-2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04740476 An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome Phase 2 Interventional Stoke Therapeutics, Inc The SWALLOWTAIL study
NCT04442295 An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome Phase 1/Phase 2 Interventional Stoke Therapeutics, Inc The MONARCH study
NCT06872125 A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome Phase 3 Interventional Stoke Therapeutics, Inc